Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells

BackgroundTreatment of B-cell malignancies with CD19-directed chimeric antigen receptor (CAR) T-cells marked a new era in immunotherapy, which yet has to be successfully adopted to solid cancers. Epigenetic inhibitors of DNA methyltransferases (DNMTi) and histone deacetylases (HDACi) can induce broa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Camilla M. Grunewald, Corinna Haist, Carolin König, Patrick Petzsch, Arthur Bister, Elfriede Nößner, Constanze Wiek, Kathrin Scheckenbach, Karl Köhrer, Günter Niegisch, Helmut Hanenberg, Michèle J. Hoffmann
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/512c4135cac04c4ea5c0bf21f0fa8e19
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:512c4135cac04c4ea5c0bf21f0fa8e19
record_format dspace
spelling oai:doaj.org-article:512c4135cac04c4ea5c0bf21f0fa8e192021-11-17T04:34:05ZEpigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells1664-322410.3389/fimmu.2021.782448https://doaj.org/article/512c4135cac04c4ea5c0bf21f0fa8e192021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.782448/fullhttps://doaj.org/toc/1664-3224BackgroundTreatment of B-cell malignancies with CD19-directed chimeric antigen receptor (CAR) T-cells marked a new era in immunotherapy, which yet has to be successfully adopted to solid cancers. Epigenetic inhibitors of DNA methyltransferases (DNMTi) and histone deacetylases (HDACi) can induce broad changes in gene expression of malignant cells, thus making these inhibitors interesting combination partners for immunotherapeutic approaches.MethodsUrothelial carcinoma cell lines (UCC) and benign uroepithelial HBLAK cells pretreated with the DNMTi decitabine or the HDACi romidepsin were co-incubated with CAR T-cells directed against EGFR or CD44v6, and subsequent cytotoxicity assays were performed. Effects on T-cell cytotoxicity and surface antigen expression on UCC were determined by flow cytometry. We also performed next-generation mRNA sequencing of inhibitor-treated UCC and siRNA-mediated knockdown of potential regulators of CAR T-cell killing.ResultsExposure to decitabine but not romidepsin enhanced CAR T-cell cytotoxicity towards all UCC lines, but not towards the benign HBLAK cells. Increased killing could neither be attributed to enhanced target antigen expression (EGFR and CD44v6) nor fully explained by changes in the T-cell ligands PD-L1, PD-L2, ICAM-1, or CD95. Instead, gene expression analysis suggested that regulators of cell survival and apoptosis were differentially induced by the treatment. Decitabine altered the balance between survival and apoptosis factors towards an apoptosis-sensitive state associated with increased CAR T-cell killing, while romidepsin, at least partially, tilted this balance in the opposite direction. Knockdown experiments with siRNA in UCC confirmed BID and BCL2L1/BCLX as two key factors for the altered susceptibility of the UCC.ConclusionOur data suggest that the combination of decitabine with CAR T-cell therapy is an attractive novel therapeutic approach to enhance tumor-specific killing of bladder cancer. Since BID and BCL2L1 are essential determinants for the susceptibility of a wide variety of malignant cells, their targeting might be additionally suitable for combination with immunotherapies, e.g., CAR T-cells or checkpoint inhibitors in other malignancies.Camilla M. GrunewaldCorinna HaistCorinna HaistCarolin KönigPatrick PetzschArthur BisterArthur BisterElfriede NößnerConstanze WiekKathrin ScheckenbachKarl KöhrerGünter NiegischHelmut HanenbergHelmut HanenbergMichèle J. HoffmannFrontiers Media S.A.articleepigenetic inhibitorsbladder cancerchimeric antigen receptorimmunotherapyT-cellImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution DOAJ
collection DOAJ
language EN
topic epigenetic inhibitors
bladder cancer
chimeric antigen receptor
immunotherapy
T-cell
Immunologic diseases. Allergy
RC581-607
spellingShingle epigenetic inhibitors
bladder cancer
chimeric antigen receptor
immunotherapy
T-cell
Immunologic diseases. Allergy
RC581-607
Camilla M. Grunewald
Corinna Haist
Corinna Haist
Carolin König
Patrick Petzsch
Arthur Bister
Arthur Bister
Elfriede Nößner
Constanze Wiek
Kathrin Scheckenbach
Karl Köhrer
Günter Niegisch
Helmut Hanenberg
Helmut Hanenberg
Michèle J. Hoffmann
Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
description BackgroundTreatment of B-cell malignancies with CD19-directed chimeric antigen receptor (CAR) T-cells marked a new era in immunotherapy, which yet has to be successfully adopted to solid cancers. Epigenetic inhibitors of DNA methyltransferases (DNMTi) and histone deacetylases (HDACi) can induce broad changes in gene expression of malignant cells, thus making these inhibitors interesting combination partners for immunotherapeutic approaches.MethodsUrothelial carcinoma cell lines (UCC) and benign uroepithelial HBLAK cells pretreated with the DNMTi decitabine or the HDACi romidepsin were co-incubated with CAR T-cells directed against EGFR or CD44v6, and subsequent cytotoxicity assays were performed. Effects on T-cell cytotoxicity and surface antigen expression on UCC were determined by flow cytometry. We also performed next-generation mRNA sequencing of inhibitor-treated UCC and siRNA-mediated knockdown of potential regulators of CAR T-cell killing.ResultsExposure to decitabine but not romidepsin enhanced CAR T-cell cytotoxicity towards all UCC lines, but not towards the benign HBLAK cells. Increased killing could neither be attributed to enhanced target antigen expression (EGFR and CD44v6) nor fully explained by changes in the T-cell ligands PD-L1, PD-L2, ICAM-1, or CD95. Instead, gene expression analysis suggested that regulators of cell survival and apoptosis were differentially induced by the treatment. Decitabine altered the balance between survival and apoptosis factors towards an apoptosis-sensitive state associated with increased CAR T-cell killing, while romidepsin, at least partially, tilted this balance in the opposite direction. Knockdown experiments with siRNA in UCC confirmed BID and BCL2L1/BCLX as two key factors for the altered susceptibility of the UCC.ConclusionOur data suggest that the combination of decitabine with CAR T-cell therapy is an attractive novel therapeutic approach to enhance tumor-specific killing of bladder cancer. Since BID and BCL2L1 are essential determinants for the susceptibility of a wide variety of malignant cells, their targeting might be additionally suitable for combination with immunotherapies, e.g., CAR T-cells or checkpoint inhibitors in other malignancies.
format article
author Camilla M. Grunewald
Corinna Haist
Corinna Haist
Carolin König
Patrick Petzsch
Arthur Bister
Arthur Bister
Elfriede Nößner
Constanze Wiek
Kathrin Scheckenbach
Karl Köhrer
Günter Niegisch
Helmut Hanenberg
Helmut Hanenberg
Michèle J. Hoffmann
author_facet Camilla M. Grunewald
Corinna Haist
Corinna Haist
Carolin König
Patrick Petzsch
Arthur Bister
Arthur Bister
Elfriede Nößner
Constanze Wiek
Kathrin Scheckenbach
Karl Köhrer
Günter Niegisch
Helmut Hanenberg
Helmut Hanenberg
Michèle J. Hoffmann
author_sort Camilla M. Grunewald
title Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
title_short Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
title_full Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
title_fullStr Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
title_full_unstemmed Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
title_sort epigenetic priming of bladder cancer cells with decitabine increases cytotoxicity of human egfr and cd44v6 car engineered t-cells
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/512c4135cac04c4ea5c0bf21f0fa8e19
work_keys_str_mv AT camillamgrunewald epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT corinnahaist epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT corinnahaist epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT carolinkonig epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT patrickpetzsch epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT arthurbister epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT arthurbister epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT elfriedenoßner epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT constanzewiek epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT kathrinscheckenbach epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT karlkohrer epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT gunterniegisch epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT helmuthanenberg epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT helmuthanenberg epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
AT michelejhoffmann epigeneticprimingofbladdercancercellswithdecitabineincreasescytotoxicityofhumanegfrandcd44v6carengineeredtcells
_version_ 1718425987694198784